



OFFICE OF THE DIRECTOR

Kate Brown, Governor



500 Summer St NE E20

Salem OR 97301

Voice: 503-947-2340

Fax: 503-947-2341

www.Oregon.Gov/OHA

www.health.oregon.gov

**OFFICIAL WEBSITE NOTICE**

**Posting Date: August 23, 2016**

**RECOMMENDATIONS OF DRUG USE REVIEW / PHARMACY AND THERAPEUTICS COMMITTEE**

The Oregon Drug Use Review / Pharmacy and Therapeutics Committee met in Salem, Oregon on Thursday, July 28, 2016. The Committee considered in order of priority: the safety and efficacy of the drugs being considered, the ability of Oregonians to access effective prescription drugs that are appropriate for their clinical conditions and finally, substantial differences in costs of drugs within the same therapeutic class. Based upon the clinical information presented by staff<sup>i</sup> and all public comment offered,<sup>ii</sup> while considering the impact on special populations, the Committee makes the following recommendations for the Oregon Practitioner-Managed Prescription Drug Plan (PMPDP) or for any other preferred drug list established by the Oregon Health Authority:

**Drug Use Review Recommendations:**

ADHD Policy Evaluation

The Committee agreed that no further research is needed at this time and recommended updating the current PA policy to approve lisdexamfetamine for binge eating disorder only for adults with an absence of co-morbid mental health illness and amend PA criteria to require CBT. The Committee also approved the recommendation to streamline PA processing for stable ADHD regimens for children and for staff to perform RetroDUR outreach and fax prescribers change order forms to promote switching clients to preferred products. After comparative cost consideration in executive session, the Committee recommended making methylphenidate patches (Daytrana®) non-preferred on the PMPDP.

<u>DRUG</u>	<u>CHANGE</u>
<u>Methylphenidate patch</u>	<u>Make non-preferred on the PMPDP</u>

**Practitioner-Managed Prescription Drug Plan (PMPDP) Recommendations:**

Smoking Cessation Drug Class Update

The Committee agreed that no further research is needed at this time and recommended no changes to the PDL based on the clinical evidence.

After comparative cost consideration in executive session the Committee recommended making no changes to the PMPDP.

#### Antidepressants Scan

The Committee recommended that no further research is needed at this time and after comparative cost consideration in executive session the Committee recommended making no changes to the PMPDP.

#### Erythropoiesis Stimulating Agents Scan

The Committee recommended that no further research is needed at this time and to maintain the current PA criteria. After comparative cost consideration in executive session the Committee recommended making no changes to the PMPDP.

#### Antivirals for Herpes Simplex Virus Scan

The Committee recommended that no further research is needed at this time and to adopt the proposed changes to the PA criteria. After comparative cost consideration in executive session the Committee recommended making no changes to the PMPDP.

#### Drugs for Benign Prostatic Hypertrophy (BPH) Scan

The Committee recommended that no further research is needed at this time and after comparative cost consideration in executive session the Committee recommended making no changes to the PMPDP.

#### Anti-Parkinson's Agents Scan

The Committee recommended that no further research is needed at this time and after comparative cost consideration in executive session the Committee recommended making no changes to the PMPDP.

#### Bone Resorption Inhibitors and Related Agents Scan

The Committee recommended that no further research is needed at this time and after comparative cost consideration in executive session the Committee recommended making no changes to the PMPDP.

#### Antiepileptic Drug Class Update and brivaracetam New Drug Evaluation (NDE)

The Committee recommended that no further research is needed at this time and to maintain brivaracetam as non-preferred on the PMPDP. After comparative cost consideration in executive session the Committee recommended making no changes to the PMPDP.

#### Direct-acting Oral Anticoagulants Class Update

The Committee recommended no changes to the PMPDP based on the DERP report and to continue open access to all DOACs without PA.

Lesinurad NDE

The Committee recommended maintaining lesinurad as non-preferred on the PMPDP.

Monoclonal Antibodies for Asthma Class Review

The Committee recommended maintaining mepolizumab and reslizumab as non-preferred on the PMPDP and to adopt the proposed PA criteria as amended to require the approved age  $\geq 12$  years for mepolizumab.


The Committee has made these recommendations to the Oregon Health Authority for approval by the Director of the Oregon Health Authority.

**APPROVAL BY THE DIRECTOR OF THE OREGON HEALTH AUTHORITY**

The recommendations of the Drug Use Review / Pharmacy and Therapeutics Committee are approved. Recommendations with respect to the inclusion of a drug on the Practitioner-Managed Prescription Drug Plan will be put into place no earlier than 60 days from the date this notice is posted on the web site.



Lynne Saxton  
Director, Oregon Health Authority



Approval date

A request for reconsideration of this decision to adopt the recommendations of the Drug Use Review / Pharmacy and Therapeutics Committee must be filed with and received by the Director no later than 30 calendar days from the date of this notice. 2011 OR law, CH 730 (HB2100) Section 4

<sup>i</sup>[http://www.orpdl.org/durm/meetings/meetingdocs/2016\\_07\\_28/finals/2016\\_07\\_28\\_PnT\\_Complete.pdf](http://www.orpdl.org/durm/meetings/meetingdocs/2016_07_28/finals/2016_07_28_PnT_Complete.pdf)

<sup>ii</sup>No written testimony was submitted for this meeting